MXiPr

The onset is gentle and carries an immediate note of warmth — a physical glow that begins in the chest and expands outward through the torso and into the limbs within fifteen to twenty minutes. It has something of ketamine's familiar signature but friendlier, more inviting, as though ketamine has put on a soft sweater and decided to be kind. The body grows pleasantly heavy, sinking into its surface, and a subtle softening of visual edges suggests that the dissociation is beginning to do its quiet work.

The come-up is where MXiPr distinguishes itself. The warmth intensifies into something genuinely euphoric — not the sharp, stimulant euphoria of the arylcyclohexylamines but a diffuse, serotonergic glow that resembles the entactogenic quality of substances from an entirely different pharmacological family. Sound deepens and enriches; music becomes immersive and emotionally charged, each song acquiring a personal significance that it may not ordinarily possess. Vision begins to shift — colors become more saturated, depth perception subtly alters, and in dim lighting, faint geometric patterns may begin to emerge on surfaces: slow, breathing tessellations that respond to your attention.

At the peak, the dissociation and the visual component merge into something remarkable for a compound in this class. Closed-eye visuals are vivid and colorful: flowing mandalas, spiraling tunnels of light, organic forms that pulse and breathe with your heartbeat. There is a psychedelic quality here that goes well beyond the usual dissociative repertoire — a sense of visual richness that recalls tryptamines more than arylcyclohexylamines. The body is deeply relaxed, almost melted into its surroundings, and the emotional tone is one of quiet awe and gratitude. Music at this point is transcendent, each note arriving with a visual and emotional depth that makes you want to laugh and cry simultaneously.

The duration is moderate — three to four hours at most — and the descent is smooth and even-tempered. The warmth fades gradually, the visuals dim, and the world reasserts its ordinary density without harshness or abruptness. There is a pleasant afterglow that lasts an hour or two: a residual warmth, a lingering appreciation for music and texture, a sense of having been somewhere genuinely beautiful. Sleep comes easily and is restful. MXiPr leaves you the way a good guest leaves a house — with warmth, with gratitude, and with the feeling that you would welcome it back.

Mechanism

MXiPr's pharmacology is inferred from structural similarity to MXE. The shared core structure (3-methoxy phenyl ring, 2'-oxo cyclohexyl group) suggests:

• NMDA receptor antagonism — the primary mechanism of all arylcyclohexylamines
• Possible SERT inhibition — the feature that distinguishes MXE from ketamine, likely retained in MXiPr given structural similarity

Effect of Isopropyl Substitution

The N-isopropyl group is larger and more branched than MXE's N-ethyl group. Consequences:

• Increased lipophilicity — potentially faster CNS penetration
• Altered receptor binding geometry — may shift selectivity or affinity at NMDA and serotonin receptors
• Different metabolic handling — hepatic CYP450 processing of isopropyl groups differs from ethyl groups
• Potentially different duration and onset kinetics

Without formal binding studies, whether the isopropyl substitution makes MXiPr more or less potent than MXE, or substantially shifts its pharmacological profile, cannot be determined with confidence.

Duration

MXiPr is expected to have a similar or somewhat longer duration than MXE based on the metabolic considerations of the isopropyl group. Pharmacokinetic data are not available.

Development Context

MXiPr emerged as part of the post-MXE wave of structural analogs, developed as MXE's scheduling removed it from legal markets. The isopropyl modification represents a straightforward N-substituent change in the MXE-analog series — one of multiple such changes (methyl, ethyl, isopropyl, cyclopropyl) that chemists explored in the effort to produce MXE-like compounds outside newly enacted scheduling.

Research Chemical Status

MXiPr occupies a niche position in the research chemical market — available but without the community engagement necessary to generate meaningful harm reduction knowledge. Its role as an MXE structural variant gives it scientific interest in the context of SAR research, but limited independent community significance.